If anyone else knows that answer or where to find it, please leave a comment below
(CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history
The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations
Studies show that consuming protein particularly alongside calcium can significantly enhance the bodys natural production of GLP-1 by activating amino acid-sensitive receptors in the gut.[3] Examples of high-protein foods that support GLP-1 production include: High-fibre foods may also support GLP-1 release
Retatrutides unique mechanism, particularly via glucagon receptor activation, enhances mitochondrial function and fat oxidation pathways, enabling the body to better adapt to periods of fasting, dietary changes, and physical stress
There's this sense of urgency that's driving people to make rash decisions, he says
